The estimated Net Worth of Paula B Stafford is at least 911 千$ dollars as of 26 March 2021. Ms Stafford owns over 70,000 units of Novan Inc stock worth over 13,562$ and over the last 7 years she sold NOVN stock worth over 0$. In addition, she makes 897,864$ as Pres、 CEO & Chairwoman at Novan Inc.
Ms has made over 2 trades of the Novan Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 70,000 units of NOVN stock worth 100,100$ on 26 March 2021.
The largest trade she's ever made was buying 80,693 units of Novan Inc stock on 17 May 2019 worth over 154,931$. On average, Ms trades about 15,069 units every 68 days since 2017. As of 26 March 2021 she still owns at least 150,693 units of Novan Inc stock.
You can see the complete history of Ms Stafford stock trades at the bottom of the page.
Paula Brown Stafford is the Pres, CEO & Chairwoman at Novan Inc.
As the Pres、 CEO & Chairwoman of Novan Inc, the total compensation of Ms Stafford at Novan Inc is 897,864$. There are no executives at Novan Inc getting paid more.
Ms Stafford is 55, she's been the Pres、 CEO & Chairwoman of Novan Inc since . There are 8 older and 4 younger executives at Novan Inc. The oldest executive at Novan Inc is Robert Ingram, 77, who is the Independent Director.
Paula's mailing address filed with the SEC is C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC, 27703.
Over the last 8 years, insiders at Novan Inc have traded over 72,487$ worth of Novan Inc stock and bought 1,476,993 units worth 9,839,419$ . The most active insiders traders include John W Palmour、Robert J Keegan、Life Sciences Holdings Ltd .... On average, Novan Inc executives and independent directors trade stock every 70 days with the average trade being worth of 4,566$. The most recent stock trade was executed by Machelle Sanders on 27 June 2023, trading 11,553 units of NOVN stock currently worth 4,737$.
novan, inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. we believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.
Novan Inc executives and other stock owners filed with the SEC include: